13698-56-1

Upstream product

• 349636-49-3 5-[4-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)benzylidene]-2-iminothiazolidin-4-one 
• 391904-97-5 5-[4-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-benzyl]-thiazolidine-2,4-dione 
• 349636-57-3 1-[4-(2-imino-4-oxothiazolidin-5-ylmethyl)phenyl]piperidin-4-one 
• 349636-51-7 5-[4-(4-oxopiperidin-1-yl)benzylidene]thiazolidine-2,4-dione 
• 344604-91-7 5-[4-(4-oxopiperidin-1-yl)benzyl]thiazolidine-2,4-dione 
• 14336-30-2 N-[2-benzyloxy-5-(2-dibenzylamino-1-oxoethyl)phenyl]methanesulfonamide 
• 373359-50-3 N-[2-benzyloxy-5-(2-dibenzylamino-1-hydroxyethyl)phenyl]methanesulfonamide 

Downstream Products

• 121277-48-3 N-[2-Hydroxy-5-[1-hydroxy-2-[[6-[4-(2-quinolinyl)butoxy]hexyl]amino]ethyl]phenyl]methanesulphonamide, benzoate salt 
• 123954-65-4 N-[5-[2-[[6-[[6-(2-furanyl)hexyl]oxy]hexyl]amino]-1-hydroxyethyl]-2-hydroxyphenyl]methanesulphonamide, benzoate salt 
• 121798-77-4 N-[2-Hydroxy-5-[1-hydroxy-2-[[6-[(3-phenylpropyl)thio]hexyl]amino]ethyl]phenyl]methanesulphonamide benzoate salt 

Relevant academic research and scientific papers

2-substituted thiazolidinones as beta-3 adrenergic receptor agonists

This invention provides compounds of Formula I having the structure wherein: A, X, Y, Z, R1, R2, R3, R4, R5, and R6are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

Novel (4-piperidin-1-yl)-phenyl sulfonamides as potent and selective human β3 agonists

A series of novel (4-piperidin-1-yl)-phenyl sulfonamides was prepared and evaluated for their biological activity on the human β3-adrenergic receptor (AR). Replacement of the 3,4-dihydroxyl group of the catechol moiety with 4-hydroxyl-3-methyl